Journal: Frontiers in Immunology

Article Title: Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and in vitro evidence of epithelial injury, barrier impairment, and inflammatory responses

doi: 10.3389/fimmu.2026.1934652

Figure Lengend Snippet: Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, capecitabine, trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.

Article Snippet: 5-Fluorouracil (5-FU,TargetMol, USA, T0984), capecitabine (TargetMol, USA,T1408), and trifluridine ( T70086 ,Psaitong Biotechnology, Beijing,China.)

Techniques: Analysis

Journal: PLOS Pathogens

Article Title: Single amino acid substitution in RdRp reduces viral recombination frequency of NADC30-like porcine reproductive and respiratory syndrome virus type 2

doi: 10.1371/journal.ppat.1014500

Figure Lengend Snippet: HeB108 and its ribavirin-associated mutants were inoculated into Marc-145 cells that were pre-treated with ribavirin (A) or 5-FU (B) at an MOI of 0.01 for 72 h. HuN4 and its ribavirin-associated mutants were inoculated into Marc-145 cells that were pre-treated with ribavirin (C) or 5-FU (D) . Cells without ribavirin or 5-FU treatment served as a control to evaluate the virus titers. Viral genomic RNA level was determined by RT-qPCR. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Article Snippet: Monolayers of Marc-145 cells were pre-treated with 100, 200, 300, and 350 μM ribavirin, or 400 and 600 μM 5-fluorouracil (5-FU) (MCE, China) for 2 h. The cells were infected with site-directed mutated or parental virus at an MOI of 0.01 for 2 h. The infected cells were washed three times with PBS.

Techniques: Control, Virus, Quantitative RT-PCR